Publications by authors named "Matt Mixdorf"
Development of [Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.
Eur J Nucl Med Mol Imaging
May 2021
Article Synopsis
- Multiple myeloma (MM) is a challenging bone marrow cancer, and elotuzumab is an FDA-approved treatment that targets the CS1 protein, which is found in high amounts in MM cells.
- The study developed a PET tracer called [Zr]DFO-elotuzumab to visualize CS1 expression in MM for identifying which patients might benefit from this therapy.
- Results showed that [Zr]DFO-elotuzumab effectively localized to tumor sites with high specificity, making it a promising companion diagnostic tool for CS1-targeted treatments.